Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer

Brain, Behavior, and Immunity

Volumn 22, Issue 1, 2008, Pages 98-104

  Mills, Paul J ^a,e,f   Ancoli Israel, Sonia ^a,e,f,g   Parker, Barbara ^b,e   Natarajan, Loki ^c,e   Hong, Suzi ^a,f   Jain, Shamini ^a,f   Sadler, Georgia R ^d,e,g   Känel, Roland von ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^h UNIVERSITY OF BERN   (Switzerland)

Author keywords

Breast cancer; Chemotherapy; CRP; IL 6; IL1 RA; Inflammation; sICAM 1; sP selectin; TNF ; VEGF; vWf

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; PADGEM PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MARKER; ENDOTHELIUM CELL; FEMALE; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; MULTIPLE REGRESSION; PREDICTION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; TREATMENT RESPONSE;

ADULT; AGED; ANTHRACYCLINES; BIOLOGICAL MARKERS; BREAST NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MIDDLE AGED; P-SELECTIN; PREDICTIVE VALUE OF TESTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON WILLEBRAND FACTOR;

EID: 36749034739     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2007.07.001     Document Type: Article

References (43)

1. Albuquerque K.V., Price M.R., Badley R.A., Jonrup I., Pearson D., Blamey R.W., and Robertson J.F. Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. Eur. J. Surg. Oncol. 21 (1995) 504-509
2. Bachelot T., Ray-Coquard I., Menetrier-Caux C., Rastkha M., Duc A., and Blay J.Y. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. British J. Cancer 88 (2003) 1721-1726
3. Berberoglu U., Yildirim E., and Celen O. Serum levels of tumor necrosis factor-α correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer. Int. J. Biol. Markers 19 (2004) 130-134
4. Blann A.D., Byrne G.J., and Baildam A.D. Increased soluble intercellular adhesion molecule-1, breast cancer and the acute phase response. Blood Coagul. Fibrinolysis 13 (2002) 165-168
5. Blann A.D., Gurney D., Wadley M., Bareford D., Stonelake P., and Lip G.Y. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul. Fibrinolysis 12 (2001) 43-50
6. Boudreau N., and Myers C. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res 5 (2003) 140-146
7. Bozcuk H., Uslu G., Samur M., Yildiz M., Ozben T., Ozdogan M., Artac M., Altunbas H., Akan I., and Savas B. Tumour necrosis factor-α, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 27 (2004) 58-65
8. Caine G.J., Stonelake P.S., Lip G.Y., and Blann A.D. Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer. Cancer Lett. (2006)
9. Cho D.H., Song H.K., Kang H.S., Yoon S.R., Lee H.G., Pyun K.H., Lee W.J., Kim Y.B., and Choi I. Ligation of ICAM-1 molecules inhibits target cell-induced granule exocytosis of IL-12-activated natural killer cells. Cell Immunol. 199 (2000) 1-7
10. Cottu P.H., Extra J.M., Espie M., Marolleau J.P., de Roquancourt A., Makke J., Miclea J.M., Laurence V., Mayeur D., Lerebours F., Cuvier C., and Marty M. High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study. British J. Cancer 85 (2001) 1240-1246
11. Fontanini G., Campani D., Roncella M., Cecchetti D., Calvo S., Toniolo A., and Basolo F. Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma. British J Cancer 80 (1999) 579-584
12. Fox S.B., Turner G.D., Gatter K.C., and Harris A.L. The increased expression of adhesion molecules ICAM-3, E- and P-selectins on breast cancer endothelium. J. Pathol. 177 (1995) 369-376
13. Fuksiewicz M., Kaminska J., Kotowicz B., Kowalska M., Rubach M., and Pienkowski T. Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patients. Clin. Chem. Lab Med. 44 (2006) 1092-1097
14. Kaihara A., Iwagaki H., Gouchi A., Hizuta A., Isozaki H., Takakura N., and Tanaka N. Soluble intercellular adhesion molecule-1 and natural killer cell activity in gastric cancer patients. Res. Commun. Molecular Pathol. Pharmacol. 100 (1998) 283-300
15. Kanabrocki E.L., Sothern R.B., Messmore H.L., Roitman-Johnson B., McCormick J.B., Dawson S., Bremner F.W., Third J.L., Nemchausky B.A., Shirazi P., and Scheving L.E. Circadian interrelationships among levels of plasma fibrinogen, blood platelets, and serum interleukin-6. Clin. Appl. Thromb. Hemost. 5 (1999) 37-42
16. Klein B., Levin I., Kfir B., Mishaeli M., Shapira J., and Klein T. The significance of soluble interleukin-2, soluble interleukin-2 receptors, soluble ICAM-1 and beta 2-microglobulin in breast cancer patients. Tumour Biol. 16 (1995) 290-296
17. Knupfer H., and Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat (2006)
18. Kummel S., Eggemann H., Luftner D., Thomas A., Jeschke S., Zerfel N., Heilmann V., Emons G., Zeiser T., Ulm K., Kobl M., Korlach S., Schmid P., Sehouli J., Elling D., and Blohmer J.U. Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes. Anticancer Res. 26 (2006) 1719-1726
19. Lithgow D., and Covington C. Chronic inflammation and breast pathology: a theoretical model. Biol. Res. Nurs. 7 (2005) 118-129
20. Mendonca M.A., Cunha F.Q., Murta E.F., and Tavares-Murta B.M. Failure of neutrophil chemotactic function in breast cancer patients treated with chemotherapy. Cancer Chemother. Pharmacol. 57 (2006) 663-670
21. Merendino R.A., Gangemi S., Ruello A., Bene A., Losi E., Lonbardo G., and Purello-Dambrosio F. Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations. Int. J. Biol. Markers 16 (2001) 126-129
22. Mettler L., Salmassi A., Heyer M., Schmutzier A., Schollmeyer T., and Jonat W. Perioperative levels of interleukin-1beta and interleukin-6 in women with breast cancer. Clin. Exp. Obstet. Gynecol. 31 (2004) 20-22
23. Miller R.G. Simultaneous Statistical Inference (1981), Springer-Verlag Springer Series in Statistics
24. Mills P.J., Parker B., Jones V., Adler K.A., Perez C.J., Johnson S., Cohen-Zion M., Marler M., Sadler G.R., Dimsdale J.E., and Ancoli-Israel S. The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer. Clin. Cancer Res. 10 (2004) 4998-5003
25. Muc-Wierzgon M., Madej K., Baranowski M., and Kokot T. Fluctuation of endogenous TNF-α concentration in plasma in advanced cancer patients. J. Biol. Regul. Homeost. Agents 10 (1996) 25-26
26. Nicolini A., Carpi A., and Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev. (2006)
27. Nishimura R., Nagao K., Miyayama H., Matsuda M., Baba K., Yamashita H., and Fukuda M. Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer. Breast Cancer (Tokyo, Japan) 10 (2003) 120-128
28. O'Hanlon D.M., Fitzsimons H., Lynch J., Tormey S., Malone C., and Given H.F. Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur. J. Cancer 38 (2002) 2252-2257
29. Ogawa Y., Hirakawa K., Nakata B., Fujihara T., Sawada T., Kato Y., Yoshikawa K., and Sowa M. Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin. Cancer Res. 4 (1998) 31-36
30. Ottosson S., Magnusson K., and Hultborn R. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery. Anticancer Res. 19 (1999) 4429-4434
31. Pusztai L., Mendoza T.R., Reuben J.M., Martinez M.M., Willey J.S., Lara J., Syed A., Fritsche H.A., Bruera E., Booser D., Valero V., Arun B., Ibrahim N., Rivera E., Royce M., Cleeland C.S., and Hortobagyi G.N. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25 (2004) 94-102
32. Roberts W.L., Moulton L., Law T.C., Farrow G., Cooper-Anderson M., Savory J., and Rifai N. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin. Chem. 47 (2001) 418-425 Part 2
33. Shirai A., Furukawa M., and Yoshizaki T. Expression of intercellular adhesion molecule (ICAM)-1 in adenoid cystic carcinoma of the head and neck. Laryngoscope 113 (2003) 1955-1960
34. Singer C.F., Kronsteiner N., Hudelist G., Marton E., Walter I., Kubista M., Czerwenka K., Schreiber M., Seifert M., and Kubista E. Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1α protein secretion is correlated with malignant phenotype. Clin. Cancer Res. 9 (2003) 4877-4883
35. Tsavaris N., Kosmas C., Vadiaka M., Kanelopoulos P., and Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. British J. Cancer 87 (2002) 21-27
36. Ueno T., Chow L.W., and Toi M. Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients. Biomed. Pharmacother. 60 (2006) 277-279
37. Vasse M., Thibout D., Paysant J., Legrand E., Soria C., and Crepin M. Decrease of breast cancer cell invasiveness by sodium phenylacetate (NaPa) is associated with an increased expression of adhesive molecules. British J. Cancer 84 (2001) 802-807
38. von Kanel R., Dimsdale J.E., Ziegler M.G., Mills P.J., Patterson T.L., Lee S.K., and Grant I. Effect of acute psychological stress on the hypercoagulable state in subjects (spousal caregivers of patients with Alzheimer's disease) with coronary or cerebrovascular disease and/or systemic hypertension. Am. J. Cardiol. 87 (2001) 1405-1408
39. Wu Y., Saldana L., Chillar R., and Vadgama J.V. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment. Int. J. Oncol. 20 (2002) 509-516
40. Yamazaki Y., and Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol Divers. (2006)
41. Yeh E.T., Tong A.T., Lenihan D.J., Yusuf S.W., Swafford J., Champion C., Durand J.B., Gibbs H., Zafarmand A.A., and Ewer M.S. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109 (2004) 3122-3131
42. Youssef G., and Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am. J. Cardiovasc. Drugs 5 (2005) 233-243
43. Zhang G.J., and Adachi I. Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopathological features and prognosis. Int. J. Oncol. 14 (1999) 71-77